What is the 13F Pro Quality Score for IBIO?

13F Pro ranks iBio, Inc. (IBIO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View IBIO's current score at https://13fpro.ai/research/IBIO (free sign-up required for the full ranking).

Where does 13F Pro source IBIO data?

All iBio, Inc. fundamentals and ownership data come directly from SEC EDGAR. iBio, Inc. files with the SEC under CIK 1420720. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is IBIO in?

iBio, Inc. (IBIO) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is IBIO research updated on 13F Pro?

IBIO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

iBio, Inc.(IBIO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1420720 IBIO stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $2.4M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

IBIO Stock Analysis & AI Quality Score

AI stock analysis and institutional research for iBio, Inc. (IBIO), a Healthcare sector company. IBIO is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $2.4m in revenue. Based on the latest XBRL financial filings (Q3 2026), iBio, Inc. reports net income of $-7.7M, free cash flow of $-6.1M. Top institutional holders of IBIO by reported 13-F value include Affinity Asset Advisors,, Frazier Life Sciences Management, L.P., EcoR1 Capital,, based on the most recent SEC filings. IBIO trades on the Nasdaq exchange and files with the SEC under CIK 1420720. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IBIO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for iBio, Inc. directly from SEC EDGAR.

Revenue

Q3 2026

$0.00

Net Income

Q3 2026

$-7.7M

Free Cash Flow

Q3 2026

$-6.1M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-78.8% YoY

$400.0KFY 2025

FY19 $2.0MFY21 $2.4MFY22 $1.9MFY25 $400.0K

Net Income

+63.5% YoY

$-18.4MFY 2025

FY19 $-17.6MFY21 $-23.2MFY22 $-50.3MFY25 $-18.4M

Operating Income

+37.4% YoY

$-18.6MFY 2025

FY19 $-15.8MFY21 $-31.1MFY22 $-29.7MFY25 $-18.6M

EPS (Diluted)

+39.4% YoY

$-1.75FY 2025

FY19 —FY21 $-0.06FY22 $-2.89FY25 $-1.75

Total Assets

-76.7% YoY

$23.2MFY 2025

FY19 $30.6MFY21 $147.0MFY22 $99.4MFY25 $23.2M

Op. Cash Flow

+59.2% YoY

$-15.3MFY 2025

FY19 $-14.0MFY21 $-30.1MFY22 $-37.5MFY25 $-15.3M

Metric	FY 2025	FY 2022	FY 2021	FY 2019	FY 2018	FY 2017
Revenue	$400.0K -78.8%	$1.9M -20.5%	$2.4M +17.5%	$2.0M +354.5%	$444.0K +12.7%	$394.0K
Net Income	$-18.4M +63.5%	$-50.3M -116.8%	$-23.2M -31.9%	$-17.6M -9.2%	$-16.1M -10.8%	$-14.5M
Operating Income	$-18.6M +37.4%	$-29.7M +4.5%	$-31.1M -97.1%	$-15.8M -11.0%	$-14.2M +0.3%	$-14.3M
EPS (Diluted)	$-1.75 +39.4%	$-2.89 -4716.7%	$-0.06	—	—	—
Total Assets	$23.2M -76.7%	$99.4M -32.4%	$147.0M +380.5%	$30.6M -29.0%	$43.1M +19.6%	$36.0M
Operating Cash Flow	$-15.3M +59.2%	$-37.5M -24.7%	$-30.1M -115.1%	$-14.0M -3.7%	$-13.5M -2.4%	$-13.2M

AI Insight: IBIO Financial Trends

iBio remains pre-revenue with accelerating losses, but equity base expanded sharply in recent quarters amid continued cash burn.

• Net loss widened from $4M (Q4 2024) to $9M (Q4 2025), then moderated to $8M (Q1 2026). Operating margin static at negative territory.

• Equity surged from $14M (Q4 2024) to $78M (Q1 2026)—likely capital raise—offsetting cumulative operating and net losses.

• Operating cash flow remained negative throughout, ranging $3M–$6M per quarter. No revenue generation across 8 quarters.

⚠ Runway dependent on equity injection pace. Q3 2025 equity jump suggests financing event; sustainability of burn rate unclear.

⚠ Q1 2026 net loss of $8M marks highest absolute loss in dataset. Cash burn acceleration risk if no inflection imminent.

AI Insight: IBIO Ratio Trends

iBio remains deeply unprofitable across all return metrics, with Q1 2026 showing modest stabilization but no meaningful path to profitability.

• ROE improved from -170.8% in Q1 2025 to -39.9% in Q1 2026, a 131pp swing. TTM ROE at -35.6% reflects recent stabilization.

• ROA similarly recovered from -89.1% in Q2 2025 to -36.0% in Q1 2026. TTM ROA now -32.2%, best level in dataset.

• ROIC declined from -42.5% in Q3 2025 to -43.1% in Q1 2026; TTM ROIC remains at -37.4%, indicating persistent value destruction.

⚠ Company generated losses across entire period—no positive operating margins or net income visible. Sustainability of business model unclear.

⚠ Q4 2025 saw sharp deterioration (ROE -63.6%, ROA -55.9%) before Q1 2026 recovery. Monitor for seasonal volatility or one-off charges.

Get alerted when IBIO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for iBio, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of IBIO

Affinity Asset Advisors, LLC
$5.9M3,107,200 sh
Frazier Life Sciences Management, L.P.
$3.7M1,953,467 sh
EcoR1 Capital, LLC
$3.0M1,583,000 sh
MILLENNIUM MANAGEMENT LLC
$2.9M1,549,850 sh
Logos Global Management LP
$2.5M1,300,000 sh
VANGUARD CAPITAL MANAGEMENT LLC
$2.1M1,088,299 sh
BALYASNY ASSET MANAGEMENT L.P.
$1.9M1,010,955 sh
Ikarian Capital, LLC
$1.8M957,062 sh
CITADEL ADVISORS LLC
$1.8M956,429 sh
Sio Capital Management, LLC
$1.7M904,268 sh

Fund	Value	Shares
Affinity Asset Advisors, LLC	$5.9M	3,107,200
Frazier Life Sciences Management, L.P.	$3.7M	1,953,467
EcoR1 Capital, LLC	$3.0M	1,583,000
MILLENNIUM MANAGEMENT LLC	$2.9M	1,549,850
Logos Global Management LP	$2.5M	1,300,000
VANGUARD CAPITAL MANAGEMENT LLC	$2.1M	1,088,299
BALYASNY ASSET MANAGEMENT L.P.	$1.9M	1,010,955
Ikarian Capital, LLC	$1.8M	957,062
CITADEL ADVISORS LLC	$1.8M	956,429
Sio Capital Management, LLC	$1.7M	904,268

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put IBIO on your watchlist

Track score changes the day iBio, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is IBIO a good stock to buy?

13F Pro's AI-powered analysis of iBio, Inc. (IBIO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IBIO are available on the IBIO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own IBIO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IBIO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of iBio, Inc.'s investment landscape.